TFLL Pharma · Molecule 05
Thymosin β4
Full-Length Molecule (TB-500) — Cytoskeleton & Tissue Repair
Thymosin Beta-4 (Tβ4) is a 43-amino-acid peptide found in virtually all human and animal cells and the body’s principal G-actin–sequestering molecule. Unlike the synthetic heptapeptide TB-500 (Ac-LKKTETQ), which isolates only Tβ4’s primary actin-binding domain, the full-length molecule retains its complete complement of functional domains — enabling research into cytoskeletal dynamics, tissue regeneration, and inflammation modulation across the peptide’s full mechanistic range. This product is supplied as a lyophilized research-grade peptide for in vitro and preclinical laboratory investigation only.
Identity
| Names |
Thymosin β4 (Tβ4) · supplied under the TB-500 label |
| Sequence |
Thymosin β4 (Tβ4) — 43-amino-acid peptide |
| Molecular formula |
C212H350N56O78S |
| Molecular weight |
Tβ4: 4963 Da (synthetic TB-500 fragment: 889 Da) |
| G-actin affinity |
Kd ≈ 0.7 µM |
| Primary node |
G-actin sequestration / cytoskeletal remodeling; ILK–Akt |
| Development |
Tβ4 characterized 1980s · RGN-259 clinical program (RegeneRx) |
Research axes
Investigational directions enabled by the published mechanism — not therapeutic claims.
-
◆Tissue repair & regeneration: cell migration and angiogenesis in dermal, corneal and cardiac models
-
◆Anti-inflammatory activity: NF-κB and inflammatory-mediator suppression in injury models
-
◆Cardiovascular & ophthalmology: ILK–Akt cardiac repair and corneal regeneration (RGN-259)
-
◆Cell migration & cytoskeletal remodeling via G-actin sequestration
Mechanism at a glance
In published models, Tβ4 sequesters G-actin via its LKKTET motif, driving cytoskeletal remodeling and directed cell migration. It activates the ILK–PINCH–Akt survival complex — linked to cardiac repair with epicardial neovascularization — and is pro-angiogenic, promoting endothelial migration. NF-κB suppression reduces inflammation in injury models.
Key literature: Bock-Marquette et al., 2004, Nature · Malinda et al., 1999 · Sosne et al., 2002 / 2007 · Smart et al., 2007.
Regulatory status
| Intended use |
Research use only — not an approved drug |
| WADA |
Prohibited (S2 — peptide hormones / growth factors) |
| Clinical stage |
Phase 2/3 trials are for full-length Tβ4 (RGN-259) |
Handling & Storage
-
◆Packaging: 5 × 5 mg lyophilized powder, sterile glass vial
-
◆Storage: Store at 2–8 °C (refrigerated)
-
◆Solubility: Dissolves readily in bacteriostatic water
-
◆Reconstitution: Use shortly after preparation for stability
-
◆Purity: HPLC-verified ≥ 98% · batch CoA
Research Quality & Scientific Integrity
◆ Purity HPLC-verified ≥ 98% with batch CoA |
◆ Evidence Peer-reviewed citations for all mechanistic claims |
◆ Transparency Evidence limitations stated per molecule |
◆ Safety Research use only — not for human or animal consumption |
For Research Use Only. This product is strictly intended for laboratory and research use only. Not suitable for human or animal consumption, diagnostic, or therapeutic use. All use must comply with local regulations and ethical research standards.
TFLL Pharma · TFLL BV · Belgium · Life Span · Health Span · Brain Span · www.tfllpharma.com